


Megakaryon



Target: Megakaryon Corporation

Outline: Development of platelet preparations using human induced pluripotent stem (hiPS) cells
(It (1) can produce a stable supply of platelets, (2) has a high safety profile and (3) makes low-medical-cost blood transfusions possible)

Authorized investment : 1 billion yen (maximum)/2 billion yen (maximum)/1.1 billion yen (maximum)



- In the field of regenerative medicine using iPS Cell, where Japan is at the forefront, Megakaryon is the leading start-up closest to world-wide commercialization
- Artificially produced platelet preparations can overcome supply constraints and the risk of viral infection associated with dependence on donated blood